Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Response Genetics Inc (RGDXQ) Com Stk USD0.01

Sell:$0.005 Buy:$0.005 Change: $0.001 (25.00%)
Market closed |  Prices as at close on 20 September 2019 | Switch to live prices |
Sell:$0.005
Buy:$0.005
Change: $0.001 (25.00%)
Deal now Deal for just £11.95 per trade in a SIPP or Fund & Share Account
Market closed |  Prices as at close on 20 September 2019 | Switch to live prices |
Sell:$0.005
Buy:$0.005
Change: $0.001 (25.00%)
Market closed |  Prices as at close on 20 September 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Response Genetics, Inc. is a life science company. The Company is engaged in the research, development, marketing and sale of pharmacogenomic tests for use in the treatment of cancer. To generate pharmacogenomic information from patient specimens for these tests, the Company uses its own methods for the extraction and analysis of nucleic acids and accessing the genetic information available from each patient sample. The Company's platforms include analysis of single biomarkers using the polymerase chain reaction method, as well as gene interrogation using microarray methods and fluorescence in situ hybridization (FISH) from paraffin or frozen tissue specimens. The Company is engaged in selling ResponseDX diagnostic testing products. The Company provides pharmacogenomic clinical trial testing services to pharmaceutical companies in the United States, Asia and Europe.

Contact details

Address:
1640 Marengo St Fl 7th
LOS ANGELES
90033-1057
United States
Telephone:
+1 (323) 2243900

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
RGDXQ
ISIN:
US76123U1051
Market cap:
$193,980
Shares in issue:
38.80 million
Sector:
Life Sciences Tools & Services
Exchange:
OTC Bulletin Board
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Thomas Bologna
    Chairman of the Board, Chief Executive Officer
  • Kevin Harris
    Chief Financial Officer, Vice President
  • Adanech Getachew
    General Counsel

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.